Parkinson’s Disease – Roche BP46441

Parkinson’s Disease Clinical Trial

Diagnosed with Parkinson’s Disease Within the Last 3 Years? 

Help Advance Research Aimed at Delaying the Progression of Movement-Related Symptoms

Profound Research is enrolling a Parkinson’s Disease study that is evaluating whether an investigational drug may help delay the progression of movement-related symptoms. 

To be eligible to participate, you must: 

• Be 40-85 years; all genders 

• Have a diagnosis of idiopathic Parkinson’s Disease for 3 months to 3 years 

• Be on a stable dose of Levodopa for at least 2 months 

• Have a BMI of 18-34 

• Be able to swallow whole capsules 

• Not have: 

• • Dyskinesia, motor fluctuations, freezing episodes or more than 2 falls per month 

• • Brain surgery for Parkinson’s Disease  

• • Huntington’s Disease 

• • Stroke 

• • Alzheimer’s Disease 

• • Lewy Body Dementia 

• • Multiple Sclerosis 

• • Significant neurologic disease 

• • Unstable/clinically significant cardiovascular disease within the last year 

• • Epilepsy/Seizures 

Additional criteria apply. 

Qualified participants will receive: 

• Study-related care and study drug at no cost 

• Financial compensation for reasonable time and travel expenses 

Number of visits and duration of study: 

•  Placebo-Controlled Phase: minimum of 104 weeks

Call us at 248-282-3640 or complete the form and our team will reach out soon to help determine your eligibility.